Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Up 0.8% in November Due to New Drug Launches and Lifting of 14-Day Prescription Limit: Crecon Report
January 14, 2014
- Pharma Biz Leaders Say New Price Cut Rule for Long-Listed Products a Painful Blow
January 10, 2014
- Daiichi Sankyo Submits NDA for Edoxaban in US
January 10, 2014
- Novartis Issues Apologies after Complaint Filing over Diovan, Vows Cooperation with Authorities
January 10, 2014
- Proposal to Reduce Basic Fees for Medical Institutions with Low Price Agreement Rates Could Have Big Impact: Mr Kono of Toho Pharmaceutical
January 10, 2014
- New IFN-Free Oral Drugs for Chronic Hepatitis C Could Create New Market
January 10, 2014
- MTPC Sets Up Medway Business Management Office Eyeing Resumption of Medway Injection Production
January 9, 2014
- Baxter Seeks Japan Approval of Recombinant Factor IX for Hemophilia B
January 9, 2014
- Takeda Initiates PIII Trials of Vedolizumab in Japan; Filing Expected in FY2017
January 9, 2014
- Daiichi Sankyo Applies for European Approval of Edoxaban
January 9, 2014
- Former Pfizer EPBU Head Matsumori Joins SBI Biotech as President
January 8, 2014
- Astellas Ties Up with ClearPath in US to Invest in RSV Vaccine Development
January 8, 2014
- NBI Files Additional Indication of Asthma for Spiriva
January 7, 2014
- Eisai Launches Epilepsy Treatment Fycompa in US
January 7, 2014
- Astellas to Transfer Fermentation Research-Related Assets to Taiho
January 7, 2014
- New Price Cut Rule for Long-Listed Products Blow to Drug Makers
January 6, 2014
- Azilva Tops SOC Ranking for Second Month in a Row in November in Both Hospital and GP Markets: Anterio
January 6, 2014
- Novartis Seeks Japanese Regulatory Approval of Psoriasis Agent Secukinumab
January 6, 2014
- Shionogi, AZ Revise Royalty Rate for Crestor
January 6, 2014
- Takeda to End Development of TAK-875 Due to Liver Safety Concerns
December 27, 2013
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…